Soligenix, Inc.
29 Emmons Drive - Suite C-10
Princeton, NJ 08540
Phone: (609) 538-8200
Fax: (609) 452-6467
E-mail: ir@soligenix.com
About Soligenix
Corporate Profile
Soligenix, Inc. is a development stage biopharmaceutical company committed to developing products to treat life-threatening side effects of cancer treatments and serious gastrointestinal diseases, and vaccines for certain bioterrorism agents. Soligenix has two areas of focus: 1) a therapeutics segment dedicated to the development of products for orphan diseases and areas of unmet medical need such as oral mucositis, pediatric Crohn's disease, acute radiation enteritis, and Graft-versus-Host disease (GVHD), and 2) a vaccine/biodefense segment to develop vaccines and therapeutics for military and civilian applications.
BioTherapeutics
Soligenix is developing proprietary formulations of oral BDP (beclomethasone 17.21-dipropionate) for the prevention/treatment of gastrointestinal disorders characterized by severe inflammation, including pediatric Crohn's disease (SGX203), acute radiation enteritis (SGX201) and chronic Graft-versus-Host disease (orBec®), as well as SGX942 for the treatment of oral mucositis.
BioDefense and Emerging Diseases
Through its Biodefense Division, Soligenix is developing countermeasures pursuant to the Biomedical Advanced Research and Development Authority (BARDA) Strategic Plan of 2011-2016 for inclusion in the US government's Strategic National Stockpile. Soligenix's lead biodefense products in development are a recombinant subunit vaccine called RiVax™, which is designed to protect against the lethal effects of exposure to ricin toxin and VeloThrax™, a vaccine against anthrax exposure. RiVax™ has been shown to be well tolerated and immunogenic in a Phase 1 clinical trial in normal volunteers. Both RiVax™ and VeloThrax™ are currently the subject of a $9.4 million National Institute of Allergy and Infectious Disease (NIAID) grant supporting development of Soligenix's new heat stabilization technology known as ThermoVax™. Soligenix is also developing OrbeShield™ for the treatment of gastrointestinal acute radiation syndrome (GI ARS) under a $600,000 NIAID Small Business Innovation Research (SBIR) grant. OrbeShieldTM has previously demonstrated statistically significant preclinical survival results in two separate canine GI ARS studies funded by the NIH.
Leadership
Partnering
Soligenix is interested in identifying new partnership and merger opportunities for its existing products as well as new in-licensing candidates in the areas of gastrointestinal, supportive cancer care, and biodefense. We can provide attractive compensation for any leads that result in new licenses at Soligenix or a new partnership for one of our existing products.
Please direct Business Development inquiries to:
Joseph Warusz, CPA, MBA
Acting Chief Financial Officer
Soligenix, Inc.
29 Emmons Drive - Suite C-10
Princeton, NJ 08540
Phone: 
(609) 538-8200
Fax: (609) 452-6467
E-mail: jwarusz@soligenix.com
For more information:
http://www.soligenix.com/news.aspx
News & Events
Tuesday, February 26, 2013
Soligenix Reports Year-End 2012 Financial Results and Highlights Recent Accomplishments
[read more] Wednesday, February 20, 2013
Soligenix Submits BARDA Contract Proposal for Development of OrbeShieldTM in GI ARS
[read more] Friday, February 08, 2013
Soligenix to Present at 15th Annual BIO CEO & Investor Conference
[read more] Monday, February 04, 2013
Soligenix Announces Formation of Oral Mucositis Medical Advisory Board
[read more] Tuesday, January 29, 2013
FDA Grants Soligenix Fast Track Designation for OrbeShield™ for the Reduction of Mortality Associated with Gastrointestinal Acute Radiation Syndrome (GI ARS)
[read more] Monday, January 07, 2013
BARDA Invites Soligenix to Submit Contract Proposal for Development of OrbeShield™ in GI ARS
[read more] Friday, January 04, 2013
Soligenix Receives IND Clearance from FDA to Initiate Program Evaluating OrbeShield™ as a Therapy for Gastrointestinal Acute Radiation Syndrome
[read more] Wednesday, January 02, 2013
FDA Grants Soligenix Orphan Drug Designation for OrbeShieldTM for Treatment after Exposure to a Radiological Disaster
[read more] Friday, December 28, 2012
Soligenix Receives $521,000 in Non-Dilutive Financing from New Jersey's Technology Business Tax Certificate Transfer Program
[read more] Thursday, December 27, 2012
Soligenix Regains North American and European Commercial Rights to Oral BDP
[read more] Tuesday, December 18, 2012
Soligenix Expands Pipeline with Acquisition of Novel Innate Defense Regulator Clinical Program
[read more] Corporate Fact Sheet
http://www.soligenix.com/pdfs/corp_fact-sheet.pdf Pipeline
Pipeline
BioTherapeutics
Beclomethasone 17,21-dipropionate (BDP) is a highly potent, topically active corticosteroid with a local effect on inflamed tissue. BDP has been marketed in the U.S. and worldwide since the early 1970s as the active pharmaceutical ingredient in a nasal spray and in a metered-dose inhaler for the treatment of allergic rhinitis and asthma in both adults and children. The rationale for its administration is that it provides a potent topical anti-inflammatory effect with less systemic toxicity than a comparably effective systemic corticosteroid.
Soligenix has several proprietary products designed to take advantage of the topical activity of BDP for the treatment of gastrointestinal inflammation: orBec
®, SGX201, and SGX203.
BioDefense and Emerging Diseases
Since 2001, a new sense of vulnerability to radiation, infectious diseases, toxins and chemical agents has generated significant research and development efforts to identify and produce innovative therapies and means to protect against threats that could be used as biological weapons. There is a growing need for products that protect the population against such agents of bioterrorism, as well as against emerging infectious diseases that could arise through natural epidemics. With very few exceptions, such products do not exist, and those that are available for current deployment are based on outdated and sometimes ineffective technologies. Many of these products will only be used in the event of an emergency.
Products to combat biological warfare or bioterrorism will be supplied to the population from medicines stored in the US Strategic National Stockpile (SNS). The federal government has previously established a special fund to acquire biological warfare countermeasures (termed Project Bioshield), which allocated $5.6 billion over a 10-year period to acquire products for the SNS. Realizing that many of these countermeasures do not yet exist, the US government has recently established the Biomedical Advanced Research and Development Authority (BARDA). The existence of BARDA creates a situation in which products arising from research, primarily sponsored by the National Institutes of Health (NIH) and the Department of Defense (DoD), can be prioritized and then developed for large-scale manufacturing and clinical evaluation, and ultimately acquisition of the product for the SNS.
Soligenix, Inc. is addressing the development of products and technologies that can be used to protect against several biological threats considered agents of bioterrorism, consistent with biological warfare threats and emerging diseases that the National Institute of Allergy and Infectious Diseases (NIAID), a division of the NIH, has identified as high priorities. Soligenix is developing several potential products to prevent morbidity and mortality due to the threat of biological toxins for which preventive vaccination is the most feasible means to protect a susceptible population. This approach is being taken because the known mechanism of protection against toxin exposure is mediated through antibodies in the serum or present on mucosal surfaces that can be elicited by vaccination with subunit immunogens.
Soligenix's process for product development of biodefense products is highly cooperative with government funding, since the government itself will be the final supplier of the products. Currently, Soligenix is operating under a $9.4 million grant award from NIAID, which will fund, over a five-year period, the development of formulation and manufacturing processes for vaccines, including RiVax™ (ricin toxin vaccine), and VeloThrax™ (anthrax vaccine) that are stable at elevated temperatures. The grant will also fund the development of improved thermostable adjuvants expected to result in rapidly acting vaccines that can be given with fewer injections over shorter intervals. In addition, Soligenix is expanding the range of applicability of its lead product, oral beclomethasone dipropionate (BDP), referred to as OrbeShield™, for gastrointestinal Acute Radiation Syndrome (ARS).
http://www.soligenix.com/
Share Structure
Shares Outstanding | 11,049,286 | a/o Feb 01, 2012 |
| |
Authorized Shares | 20,000,000 | a/o Feb 01, 2012
*Float Estimate around 6,000,000 based on insider ownership |
Insider holdings est at least 5 million shares nearly 50% of the outstanding shares (from latest insider filings avail) ^ float estimate 6mil ^
1/16/2012 Christopher J. Schaber, PhD
Chairman, President & Chief Executive Officer 333,333 Award at $0 per share. 0 08/18/2010 BAM CAPITAL LLC
192,314 Disposition at $0.24 per share. 46,155 08/18/2010 BAM CAPITAL LLC
160,000 Acquisition at $0.24 per share. 38,400 06/18/2010 Gregg Anthony Lapointe MBA, CPA
Director 975,610 Acquisition at $0.21 per share. 204,878 06/18/2010 Robert Joseph Rubin, MD
Director 243,902 Acquisition at $0.21 per share. 51,219 10/09/2009 BIOTEX PHARMA INVESTMENTS LLC
335,000 107,200 09/28/2009 BIOTEX PHARMA INVESTMENTS LLC
750,000 232,500 09/28/2009 BIOTEX PHARMA INVESTMENTS LLC
250,000 65,000 09/28/2009 Christopher J. Schaber, PhD
Chairman, President & Chief Executive Officer 79,051 Acquisition at $0.25 per share. 19,762 09/24/2009 CAVAZZA FAMILY
3,952,569 Acquisition at $0.25 per share. 988,142 09/24/2009 CAVAZZA FAMILY
3,952,569 Acquisition at $0.25 per share. 988,142 09/24/2009 CAVAZZA FAMILY
3,952,569 Acquisition at $0.25 per share. 988,142 09/18/2009 BIOTEX PHARMA INVESTMENTS LLC
250,000 67,500 07/30/2009 BIOTEX PHARMA INVESTMENTS LLC
500,000 Disposition at $0.2 per share. 100,000 07/30/2009 BIOTEX PHARMA INVESTMENTS LLC
500,000 Disposition at $0.2 per share. 100,000 08/29/2007 Evan Myrianthopoulos
Chief Financial Officer 70,000 Acquisition at $0.31 per share. 21,700 08/28/2007 Christopher J. Schaber, PhD
Chairman, President & Chief Executive Officer 100,000 Acquisition at $0.29 per share. 29,000 08/28/2007 CLAVIJO JAMES
Treasurer & Controller 35,000 Acquisition at $0.3 per share. 10,500
SNGX INSIDER OWNERSHIP LIST - LINKS - http://openinsider.com/SNGX http://www.insidercow.com/institution/subject.jsp;jsessionid=081C36AD974D102CCE9EED096D49078C?subject=0000812796&company=SNGX
http://stockcharts.com/h-sc/ui?s=SNGX&p=D&yr=2&mn=0&dy=0&id=p23172662592
Analyst Ratings *************************************************************************************
*$18.00 Target - Rodman & Renshaw have a Buy Rating target price currently for SNGX . http://bit.ly/hnxGcj
*$30.00 Target - previous Rated Buy by Brean Murray - current rating changed to Hold a/o 9/16/11
http://www.gainerstoday.com/Gains-Stock-73514-SNGX
CASH RESOURCES TOTAL APPROXIMATELY $6.2 MILLION (.56 a share) AND $9.4 MILLION NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASE (NIAID) GRANT ($1.18 a share) = Combined SNGX Valued @ ($1.74 a share)on this alone with no debt
{SNGX is Debt Free}